{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:57:10Z","timestamp":1788364630149,"version":"build-2803163510"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T00:00:00Z","timestamp":1377043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0071703","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T17:13:31Z","timestamp":1377105211000},"page":"e71703","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents"],"prefix":"10.1371","volume":"8","author":[{"given":"Noh Jin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Goos-Root","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Vaught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","article-title":"ErbB receptors and signaling pathways in cancer","volume":"21","author":"NE Hynes","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1073\/pnas.81.23.7308","article-title":"Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines","volume":"81","author":"YH Xu","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/S0021-9258(18)52354-1","article-title":"The extracellular domain of p185\/neu is released from the surface of human breast carcinoma cells, SK-BR-3","volume":"266","author":"JR Zabrecky","year":"1991","journal-title":"J Biol Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/14737159.7.3.309","article-title":"Circulating oncoproteins HER2\/neu, EGFR and CAIX (MN) as novel cancer biomarkers","volume":"7","author":"WP Carney","year":"2007","journal-title":"Expert Rev Mol Diagn"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"R Pirker","year":"2009","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","article-title":"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study","volume":"13","author":"R Pirker","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/onc.2008.19","article-title":"Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members","volume":"27","author":"DL Wheeler","year":"2008","journal-title":"Oncogene"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"A Bardelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"C Montagut","year":"2012","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-6904-11-17","article-title":"Immunogenicity of panitumumab in combination chemotherapy clinical trials","volume":"11","author":"D Weeraratne","year":"2011","journal-title":"BMC Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1096\/fj.01-0847com","article-title":"Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice","volume":"17","author":"S Planque","year":"2003","journal-title":"FASEB J"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1158\/1078-0432.CCR-03-0770","article-title":"Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer","volume":"10","author":"V Gregorc","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"AD Ellington","year":"1990","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"C Tuerk","year":"1990","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1021\/ja908035g","article-title":"Expanding the chemistry of DNA for in vitro selection","volume":"132","author":"JD Vaught","year":"2010","journal-title":"J Am Chem Soc"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"L Gold","year":"2010","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e26332","DOI":"10.1371\/journal.pone.0026332","article-title":"From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay","volume":"6","author":"S Kraemer","year":"2011","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.4161\/cbt.6.9.4539","article-title":"Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab","volume":"6","author":"ME Arteaga","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"ES Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"ref20","first-page":"487","article-title":"New insight into clinical development of nucleic acid aptamers","volume":"11","author":"CL Esposito","year":"2011","journal-title":"Discov Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"A Lievre","year":"2006","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nbt.1651","article-title":"Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins","volume":"28","author":"D Ghaderi","year":"2010","journal-title":"Nat Biotechnol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"CH Chung","year":"2008","journal-title":"N Engl J Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0071703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:33:39Z","timestamp":1646382819000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0071703"}},"subtitle":[],"editor":[{"given":"Kent E.","family":"Vrana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0071703","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]}}}